Discovery stage
Targets metabolic dysfunction-associated steatohepatitis, which is a severe type of nonalcoholic fatty liver disease (also called metabolic dysfunction-associated steatotic liver disease)
Uses small molecule targeted delivery biotechnology by ASBL